|
|
|
MIRA INFORM REPORT
|
Report No. : |
484452 |
|
Report Date : |
09.01.2018 |
IDENTIFICATION DETAILS
|
Name : |
ABBVIE INC. |
|
|
|
|
Registered Office : |
Corporation Trust Center 1209 Orange St,
Wilmington, New Castle, De, 19801, USA |
|
|
|
|
Country : |
United States |
|
|
|
|
Financials (as on) : |
31.12.2016 |
|
|
|
|
Date of Incorporation : |
04.10.2012 |
|
|
|
|
Legal Form : |
Corporation |
|
|
|
|
Line of Business : |
Subject discovers, develops, manufactures, and
sells pharmaceutical products worldwide. |
|
|
|
|
No. of Employees : |
29.000 |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd
January 2017)
|
MIRA’s Rating : |
A |
|
Credit Rating |
Explanation |
Rating Comments |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Exist |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous Rating (30.06.2017) |
Current Rating (30.09.2017) |
|
United States |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
UNITED
STATES - ECONOMIC OVERVIEW
The US has the most technologically powerful economy in the world, with a per capita GDP of $57,300. US firms are at or near the forefront in technological advances, especially in computers, pharmaceuticals, and medical, aerospace, and military equipment; however, their advantage has narrowed since the end of World War II. Based on a comparison of GDP measured at purchasing power parity conversion rates, the US economy in 2014, having stood as the largest in the world for more than a century, slipped into second place behind China, which has more than tripled the US growth rate for each year of the past four decades.
In the US, private individuals and business firms make most of the decisions, and the federal and state governments buy needed goods and services predominantly in the private marketplace. US business firms enjoy greater flexibility than their counterparts in Western Europe and Japan in decisions to expand capital plant, to lay off surplus workers, and to develop new products. At the same time, businesses face higher barriers to enter their rivals' home markets than foreign firms face entering US markets.
Long-term problems for the US include stagnation of wages for lower-income families, inadequate investment in deteriorating infrastructure, rapidly rising medical and pension costs of an aging population, energy shortages, and sizable current account and budget deficits.
The onrush of technology has been a driving factor in the gradual development of a "two-tier" labor market in which those at the bottom lack the education and the professional/technical skills of those at the top and, more and more, fail to get comparable pay raises, health insurance coverage, and other benefits. But the globalization of trade, and especially the rise of low-wage producers such as China, has put additional downward pressure on wages and upward pressure on the return to capital. Since 1975, practically all the gains in household income have gone to the top 20% of households. Since 1996, dividends and capital gains have grown faster than wages or any other category of after-tax income.
Imported oil accounts for nearly 55% of US consumption and oil has a major impact on the overall health of the economy. Crude oil prices doubled between 2001 and 2006, the year home prices peaked; higher gasoline prices ate into consumers' budgets and many individuals fell behind in their mortgage payments. Oil prices climbed another 50% between 2006 and 2008, and bank foreclosures more than doubled in the same period. Besides dampening the housing market, soaring oil prices caused a drop in the value of the dollar and a deterioration in the US merchandise trade deficit, which peaked at $840 billion in 2008. Because the US economy is energy-intensive, falling oil prices since 2013 have alleviated many of the problems the earlier increases had created.
The sub-prime mortgage crisis, falling home prices, investment bank failures, tight credit, and the global economic downturn pushed the US into a recession by mid-2008. GDP contracted until the third quarter of 2009, making this the deepest and longest downturn since the Great Depression. To help stabilize financial markets, the US Congress established a $700 billion Troubled Asset Relief Program (TARP) in October 2008. The government used some of these funds to purchase equity in US banks and industrial corporations, much of which had been returned to the government by early 2011. In January 2009, Congress passed and President Barack OBAMA signed a bill providing an additional $787 billion fiscal stimulus to be used over 10 years - two-thirds on additional spending and one-third on tax cuts - to create jobs and to help the economy recover. In 2010 and 2011, the federal budget deficit reached nearly 9% of GDP. In 2012, the Federal Government reduced the growth of spending and the deficit shrank to 7.6% of GDP. US revenues from taxes and other sources are lower, as a percentage of GDP, than those of most other countries.
Wars in Iraq and Afghanistan required major shifts in national resources from civilian to military purposes and contributed to the growth of the budget deficit and public debt. Through 2014, the direct costs of the wars totaled more than $1.5 trillion, according to US Government figures.
In March 2010, President OBAMA signed into law the Patient Protection and Affordable Care Act, a health insurance reform that was designed to extend coverage to an additional 32 million Americans by 2016, through private health insurance for the general population and Medicaid for the impoverished. Total spending on healthcare - public plus private - rose from 9.0% of GDP in 1980 to 17.9% in 2010.
In July 2010, the president signed the DODD-FRANK Wall Street Reform and Consumer Protection Act, a law designed to promote financial stability by protecting consumers from financial abuses, ending taxpayer bailouts of financial firms, dealing with troubled banks that are "too big to fail," and improving accountability and transparency in the financial system - in particular, by requiring certain financial derivatives to be traded in markets that are subject to government regulation and oversight.
In December 2012, the Federal Reserve Board (Fed) announced plans to purchase $85 billion per month of mortgage-backed and Treasury securities in an effort to hold down long-term interest rates, and to keep short-term rates near zero until unemployment dropped below 6.5% or inflation rose above 2.5%. In late 2013, the Fed announced that it would begin scaling back long-term bond purchases to $75 billion per month in January 2014 and further reduce them as conditions warranted; the Fed ended the purchases during the summer of 2014. In 2014, the unemployment rate dropped to 6.2%, and continued to fall to 5.5% by mid-2015, the lowest rate of joblessness since before the global recession began; inflation stood at 1.7%, and public debt as a share of GDP continued to decline, following several years of increases. In December 2015, the Fed raised its target for the benchmark federal funds rate by 0.25%, the first increase since the recession began. With US GDP growth below 2%, the Fed has opted to raise rates three times since then, and in mid-June 2017, the range for the target rate stood at 1% to 1.25%.
|
Source
: CIA |
STATUTORY
INFORMATION
|
Legal Name: |
ABBVIE INC. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
TradeName: |
ABBVIE INC. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ID: |
5126809 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date Created: |
2012 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date
Incorporated: |
4/10/2012 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Legal Address: |
CORPORATION TRUST CENTER 1209 ORANGE ST,
WILMINGTON, NEW CASTLE, DE, 19801, USA |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Operative
Address: |
1 North Waukegan Road North Chicago, IL 60064 United States |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Telephone: |
847-932-7900 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Fax: |
- |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Legal Form: |
CORPORATION |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Email: |
customerservice@abbvie.com |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Registered in: |
DELAWARE |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Website: |
www.abbvie.com |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Contact: |
Richard A. Gonzalez - Chairman of the
Board and Chief Executive Officer |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Staff: |
29.000 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Activity: |
SIC Code 2834,
Pharmaceutical Preparations NAICS Code 325412, Pharmaceutical Preparation Manufacturing |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
History: |
The company was incorporated in 2012 and
is based in North Chicago, Illinois. It also has collaboration agreements
with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals,
Inc.; M2Gen; Harpoon Therapeutics, Inc.; and Principia Biopharma Inc. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Key
Developments: |
AbbVie Announces Phase 3 Study of Venclexta™/
Venclyxto™ (Venetoclax) in Combination with Rituxan® Meets Its Primary
Endpoint Dec 12
17 AbbVie
announced the first presentation of efficacy and safety results from MURANO,
an international, multicenter, open-label, randomized Phase 3 study of
VENCLEXTA™/VENCLYXTO™ in combination with Rituxan® compared with bendamustine
in combination with Rituxan in patients with relapsed or refractory (R/R)
chronic lymphocytic leukemia (CLL). Investigator-assessed results showed that
patients with R/R CLL achieved significantly prolonged median
progression-free survival (PFS) with VENCLEXTA/VENCLYXTO in combination with
Rituxan [median PFS, not reached], compared with bendamustine in combination
with Rituxan [median PFS, 17.0 months; hazard ratio, 0.17; 95% CI, 0.11
"0.25; P1 Twenty-four month PFS estimates were 84.9% and 36.3%,
respectively.1 Independent Review Committee (IRC)-assessed PFS showed similar
results.1 Additionally, consistent improvement in PFS was observed across the
patient subgroups assessed in the trial, including patients with 17p deletion
[hazard ratio 0.14; 95% CI, 0.06 "0.33].1 VENCLEXTA/VENCLYXTO is being
developed by AbbVie and Roche. It is jointly commercialized by AbbVie and
Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of
the U.S. Abbvie Announces New Data on the Biologic and
Cellular Mechanisms of IMBRUVICA® (ibrutinib) in Patients with Chronic
Graft-Versus-Host Diseas Dec 11
17 AbbVie announced
new data on the biologic and cellular mechanisms of IMBRUVICA® (ibrutinib) in
patients with chronic graft-versus-host disease (cGVHD), a potentially
life-threatening consequence of an allogeneic stem cell or bone marrow
transplant. New results showed ibrutinib selectively inhibited pre-germinal
center B cells and follicular helper T cells (Tfh) that are believed to play
a critical role in treating cGVHD. In addition, the data also showed that
ibrutinib preserved immune memory and Th1 T cells, which suggests the
potential for additional treatment benefit. These results were observed in a
Phase 1b/2 trial (PCYC-1129). The data will be presented at the 59thAmerican
Society of Hematology (ASH) Annual Meeting and Exposition on Dec. 11 in
Atlanta (abstract #4481). IMBRUVICA is a first-in-class Bruton's tyrosine
kinase (BTK) inhibitor jointly developed and commercialized by Pharmacyclics
LLC, an AbbVie company, and Janssen Biotech Inc. Patients can develop GVHD, a
potentially life-threatening complication, following an allogeneic stem cell
or bone marrow transplant. The condition occurs when donor immune cells
mistakenly attack patient's normal tissues. The effects of GVHD can be seen
throughout the body, affecting almost any organ and manifesting through rashes
and skin thickening, joint pain and stiffness, eye dryness and irritation,
diarrhea, jaundice, mouth sores and ulcers, and severe lung dysfunction. The
incidence of cGVHD has continued to increase over time, with approximately
30% to 70% of post-allogeneic transplant patients developing the condition.
The U.S. Food and Drug Administration (FDA) recently granted approval of
IMBRUVICA for the treatment of adult patients with cGVHD after failure of one
or more lines of systemic therapy. This approval was based on data recently
published in Blood. Data derived from the use of Nanostring gene expression
analysis showed ibrutinib reduced inflammatory genes, including NFkB-1 and
chemokines CXCL10, CCL7 and CCL3 (2.6, 2.3, 25, and 1.8-fold decrease,
respectively), over the first three months. Additionally, a luminex plasma
quantification showed several additional chemotactic, inflammatory, and
fibrotic factors (CCL22, CXCL9, CXCL10, IL-8, sCD25, CCL4, and ST2) decreased
in 69-80% of patients treated with ibrutinib. A 42-parameter CyTOF single
cell analysis also revealed a 10-fold reduction in absolute numbers of cGVHD
implicated pre-germinal center B cells (CD19+, CD27+, CD38+, IgD+), and
notably diminished Tfh, Th17, and total B cells (2.6, 1.5, and 1.4-fold decrease,
respectively) over the first three months following ibrutinib therapy. The
relative numbers of CD4+ and CD8+ T cells remained unchanged, although the
total number of CD8+ cells seemed to follow an increasing trend. An analysis
of relative numbers of T-cell subsets indicated a trend towards increasing
numbers of Th1 and T regulatory cells, while Tfh cells and iNKT cells showed
a trend towards decreasing numbers when compared with pretreatment numbers
and 343 days of follow up. IgG plasma levels persisted while IgM
significantly decreased supporting an ibrutinib germinal center effect that
did not deplete long-lived plasma cells. Further, T cell reactivity against
influenza increased, and antibodies against EBV and tetanus remained
unchanged. However, single cell phosphorylation analysis showed BTK and
interleukin-2-inducible T-cell kinase (ITK) signaling decreased following
ibrutinib treatment in defined B and T-cell subsets. IMBRUVICA (ibrutinib) is
a first-in-class, oral, once-daily therapy that mainly works by blocking a
protein called Bruton's tyrosine kinase (BTK). BTK is a key signaling
molecule in the B-cell receptor signaling complex that plays an important
role in the survival and spread of malignant B cells as well as other
serious, debilitating conditions.5 IMBRUVICA blocks signals that tell
malignant B cells to multiply and spread uncontrollably. IMBRUVICA is
FDA-approved in six distinct patient populations: chronic lymphocytic
leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström's macroglobulinemia
(WM), along with previously-treated mantle cell lymphoma (MCL),
previously-treated marginal zone lymphoma (MZL) and previously-treated
chronic graft-versus-host disease (cGVHD). AbbVie Announces New Three-Year Follow-Up Data
from the RESONATE™-2 Study (PCYC-1115/1116) Dec 9
17 AbbVie
announced new three-year follow-up data from the RESONATE™-2 study
(PCYC-1115/1116), which found that previously-untreated chronic lymphocytic
leukemia/small lymphocytic lymphoma (CLL/SLL) patients reported sustained
improvements in measures of well-being with IMBRUVICA® (ibrutinib) versus
chemotherapy with chlorambucil. These new data provide the longest quality of
life follow up for ibrutinib to date using patient-reported outcomes (PRO).
Patients reported their quality of life outcomes for fatigue, mobility,
self-care, usual activities, pain/discomfort and anxiety/depression. At 30
months, ibrutinib was also associated with a greater progression-free
survival (PFS) rate of 85% versus chlorambucil, which had a PFS rate of 28%.
The new RESONATE-2 data will be presented at the 59thAmerican Society of
Hematology (ASH) Annual Meeting and Exposition on Dec. 9 in Atlanta (abstract
#1746). IMBRUVICA is a first-in-class Bruton's tyrosine kinase (BTK)
inhibitor jointly developed and commercialized by Pharmacyclics LLC, an
AbbVie company, and Janssen Biotech Inc. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PRINCIPAL
ACTIVITY
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
AbbVie Inc. discovers, develops,
manufactures, and sells pharmaceutical products worldwide. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Products/Services
description: |
The
company offers HUMIRA, a biologic therapy administered as a subcutaneous
injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the
treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an
interferon-free therapy, with or without ribavirin, for the treatment of
adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an
anti- human immunodeficiency virus(HIV)-1 medicine used with other anti-HIV-1
medications as a treatment that maintains viral suppression in HIV-1
patients; Norvir, a protease inhibitor indicated in combination with other
antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection
at-risk infants. In addition, the company offers AndroGel, a testosterone
replacement therapy for males diagnosed with symptomatic low testosterone;
Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency;
Synthroid to treat hypothyroidism; and Lupron, a product for the palliative
treatment of prostate cancer, endometriosis, and central precocious puberty,
as well as for the treatment of patients with anemia. Further, it provides
Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s
disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a
subcutaneous treatment for relapsing forms of multiple sclerosis. The company
sells its products to wholesalers, distributors, government agencies, health
care facilities, specialty pharmacies, and independent retailers from its
distribution centers and public warehouses. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Brands: |
Abbvie |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Sales are: |
Wholesale |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Clients: |
Index Saci Ministerio De Salud Publica Abbvie S.A.S. Abbott Laboratories De Mexico Sa De Cv Hivos International |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Suppliers: |
Anthem Biosciences Private Limited Divis Laboratories Ltd. Suven Life Sciences Limited Abbvie Operations Singapore Pte Ltd Besins Healthcare AbbVie Logistics B.V. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Operations area: |
National and International |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
The company
imports from |
INDIA SINGAPORE BELGIUM THE NETHERLANDS |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
The company
exports to |
PARAGUAY COLOMBIA MEXICO BOLIVIA |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
The subject
employs |
29.000 employees |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Payments: |
Regular |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
LOCATION
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Headquarters : |
1 North Waukegan Road North Chicago, IL 60064 United States |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Branches: |
Abbvie Inc. (Branch Location) 75 N Fairway Dr Vernon Hills, Illinois 60061-1845 United States Abbvie Inc. (Branch Location) 2425 Busse Rd Elk Grove Village, Illinois 60007-5737 United States Abbvie Inc. (Branch Location) 100 Research Dr Worcester, Massachusetts 01605-4312 United States Abbvie Inc. (Branch Location) 9615 Ave Los Romeros San Juan, Puerto Rico 00926-7036 United States |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Subsidiaries: |
AbbVie Biopharmaceuticals LLC - Delaware AbbVie Bioresearch Center Inc. -
Delaware AbbVie Biotech Ventures Inc. - Delaware AbbVie Biotherapeutics Inc. - Delaware AbbVie Endocrine Inc. - Delaware AbbVie Endocrinology Inc. - Delaware AbbVie Holdings Inc. - Delaware AbbVie Pharmaceuticals LLC - Delaware AbbVie Products LLC - Georgia AbbVie Purchasing LLC - Delaware AbbVie Resources Inc. - Delaware AbbVie Resources International Inc. -
Delaware AbbVie Respiratory LLC - Delaware AbbVie Stemcentrx LLC - Delaware AbbVie US Holdings LLC - Delaware AbbVie US LLC - Delaware AbbVie Ventures LLC - Delaware Aeropharm Technology, LLC - Delaware BioDisplay Technologies, Inc. - Illinois Fremont Holding L.L.C. – Delaware IEP Pharmaceutical Devices, LLC -
Delaware Knoll Pharmaceutical Company - New Jersey KOS Pharmaceuticals, Inc. - Delaware Life Properties Inc. - Delaware Organics L.L.C. - Delaware Pharmacyclics LLC - Delaware Rowell Laboratories, Inc. - Minnesota Sapphire Merger Sub, Inc. - Delaware Unimed Pharmaceuticals, LLC - Delaware Vernal Holdings Inc. Delaware AbbVie S.A. - Argentina AbbVie Pty Ltd - Australia AbbVie GmbH - Austria AbbVie Bahamas Ltd. - Bahamas AbbVie SA - Belgium AbbVie Ltd - Bermuda AbbVie Biotechnology Ltd - Bermuda AbbVie Holdings Unlimited - Bermuda AbbVie d.o.o. - Bosnia AbbVie Farmacęutica Ltda. - Brazil AbbVie Participaçőes Ltda. - Brazil AbbVie EOOD - Bulgaria AbbVie Corporation- Canada AbbVie Holdings Corporation - Canada Pharmacyclics Cayman Ltd. - Cayman Islands Stemcentrx Cayman Ltd. - Cayman Islands AbbVie Productos Farmacéuticos Limitada -
Chile AbbVie Pharmaceutical Trading (Shanghai)
Co., Ltd – China Pharmacyclics (Shanghai) Management
Consulting Services Limited - China AbbVie S.A.S. - Colombia AbbVie d.o.o. - Croatia AbbVie Limited - Cyprus AbbVie s.r.o. - Czech Republic AbbVie A/S - Denmark AbbVie, S.R.L. - Dominican Republic AbbVie L.L.C. - Egypt AbbVie Oy - Finland AbbVie SAS - France AbbVie Holdings SAS - France Abbott Products GmbH - Germany AbbVie Biotechnology GmbH - Germany AbbVie Deutschland GmbH & Co. KG -
Germany AbbVie Komplementär GmbH - Germany AbbVie Real Estate Management GmbH -
Germany AbbVie (Gibraltar) Holdings Limited -
Gibraltar AbbVie (Gibraltar) Limited - Gibraltar AbbVie Pharmaceuticals Societe Anonyme
-Greece AbbVie, S.A. - Guatemala AbbVie Limited -Hong Kong AbbVie Kft. - Hungary AbbVie Biopharmaceuticals Private
Limited - India AbbVie Ireland Holdings Limited -
Ireland AbbVie Ireland Unlimited Company -
Ireland AbbVie Limited - Ireland AbbVie Manufacturing Management Limited
- Ireland Fournier Laboratories Ireland Ltd. -
Ireland Pharmacyclics (Europe) Limited - Ireland AbbVie Biopharmaceuticals Ltd - Israel AbbVie S.r.l. - Italy AbbVie GK -Japan AbbVie Holdings KK - Japan AbbVie Ltd Jersey AbbVie UK Biopharmaceuticals Ltd -
Jersey AbbVie UK Ltd - Jersey AbbVie Ltd - Korea, South AbbVie SIA - Latvia AbbVie UAB - Lithuania AbbVie (Gibraltar) Holdings Limited
Luxembourg S.C.S.- Luxembourg AbbVie International S.ŕ r.l. -
Luxembourg AbbVie Investments S.ŕ r.l. - Luxembourg AbbVie Overseas S.ŕ r.l. - Luxembourg AbbVie S.ŕ r.l. - Luxembourg AbbVie Sdn. Bhd. - Malaysia AbbVie Farmacéuticos, S.A. de C.V. - Mexico AbbVie B.V. - Netherlands AbbVie Finance B.V. - Netherlands AbbVie Ireland NL B.V. - Netherlands AbbVie Japan Holdings B.V. - Netherlands AbbVie Logistics B.V - Netherlands AbbVie Nederland Holdings B.V. -
Netherlands AbbVie Pharmaceuticals B.V. -
Netherlands AbbVie Research B.V. - Netherlands AbbVie Venezuela B.V. - Netherlands AbbVie Venezuela Holdings B.V. -
Netherlands AbbVie Limited - New Zealand AbbVie AS - Norway AbbVie, S. de R.L. - Panama AbbVie Polska Sp. z o.o. - Poland AbbVie Sp. z o.o. - Poland AbbVie, L.da - Portugal AbbVie Promoçăo, L.da - Portugal AbbVie Corp - Puerto Rico Knoll LLC - Puerto Rico S.C. AbbVie S.R.L. - Romania AbbVie Limited Liability Company -
Russia AbbVie Operations Singapore Pte. Ltd. -
Singapore AbbVie Pte. Ltd. - Singapore AbbVie Holdings s.r.o. - Slovakia AbbVie s.r.o. - Slovakia AbbVie d.o.o. - Slovenia AbbVie (Pty) Ltd. - South Africa AbbVie Spain, S.L. - Spain Fundación AbbVie - Spain AbbVie AB - Sweden AbbVie AG - Switzerland AbbVie Biopharmaceuticals GmbH -
Switzerland Pharmacyclics Switzerland GmbH -
Switzerland AbbVie Ltd. - Thailand AbbVie Sarl- Tunisia AbbVie Tıbbi İlaçlar Sanayi ve
Ticaret Limited Şirketi - Turkey AbbVie Australasia Holdings Limited -
United Kingdom AbbVie Biotherapeutics Limited - United
Kingdom AbbVie Investments Limited - United
Kingdom AbbVie Ltd - United Kingdom AbbVie Trustee Company Limited - United
Kingdom AbbVie UK Holdco Limited - United
Kingdom AbbVie S.A. - Uruguay AbbVie Pharmaceuticals SCA - Venezuela |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GROUP
STRUCTURE AND SUBSIDIARY COMPANIES
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Listed at the
stock exchange: |
YES: AbbVie Inc. (ABBV) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Market
Capital: |
160.633B |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Outstanding
Shares: |
1,593,920,285 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Shareholders: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Management: |
Richard A. Gonzalez - Chairman of the
Board and Chief Executive Officer Mr. William J. Chase - Executive Vice
President & Chief Financial Officer Mr. Henry O. Gosebruch - Executive VP
& Chief Strategy Officer Ms. Laura J. Schumacher - Executive Vice
President of External Affairs, General Counsel & Corporate Secretary Mr. Michael E. Severino M.D. - Executive
Vice President of Research & Development & Chief Scientific Officer |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FINANCIAL
INFORMATION
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
We attach company’s last financial
statements. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
LEGAL
FILINGS
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
PATENTS |
COMPOSITION AND METHOD FOR THE DIAGNOSIS
AND TREATMENT OF DISEASES ASSOCIATED WITH NEURITE DEGENERATION Publication number: 20130330347 Abstract: Provided herein are antibodies
and methods of using the antibodies to treat and diagnose neurite
degenerative diseases and disorders. Type: Application Filed: January 25, 2013 Publication date: December 12, 2013 Applicants: ABBVIE INC., ABBVIE DEUTSCHLAND
GMBH & CO. KG Inventors: ABBVIE DEUTSCHLAND GMBH &
CO. KG, AbbVie Inc. COMPOSITION AND METHOD FOR THE DIAGNOSIS
AND TREATMENT OF IRON-RELATED DISORDERS Publication number: 20130330343 Abstract: Provided herein are methods of
using the antibodies that bind to RGMc to treat and diagnose iron-related
disorders. Type: Application Filed: December 13, 2012 Publication date: December 12, 2013 Applicants: AbbVie Inc., AbbVie
Deutschland GmbH & Co. KG Inventors: AbbVie Deutschland GmbH &
Co. KG, AbbVie Inc. COMPOSITION AND METHOD FOR THE DIAGNOSIS
AND TREATMENT OF IRON-RELATED DISORDERS Publication number: 20130330359 Abstract: Provided herein are antibodies
and methods of using the antibodies to treat, prevent, modulate, attenuate
and diagnose iron-related disorders. Type: Application Filed: December 13, 2012 Publication date: December 12, 2013 Applicants: AbbVie Inc., AbbVie
Deutschland GmbH & Co. KG Inventors: AbbVie Deutschland GmbH &
Co. KG, AbbVie Inc. ISOINDOLINE DERIVATIVES, PHARMACEUTICAL
COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY Publication number: 20130210880 Abstract: The present invention relates
to isoindoline derivatives of the formula (I) or a physiologically tolerated
salt thereof. The present invention also relates to pharmaceutical
compositions comprising such isoindoline derivatives, and the use of such
isoindoline derivatives for therapeutic purposes. Type: Application Filed: February 11, 2013 Publication date: August 15, 2013 Applicants: AbbVie Inc., AbbVie
Deutschland GmbH & Co. KG Inventors: AbbVie Deutschland GmbH &
Co. KG, AbbVie Inc. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GOVERNMENT
CONTRACTS |
Government Contractor: ABBVIE US LLC Name & Address: 1 N WAUKEGAN RD NORTH CHICAGO, IL 60064-1802 Number of Defense Contracts Awarded:1 Dollar Amount of Defense Contracts
Awarded:$0 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
CASES |
Hall et al v. AbbVie, Inc. et al Plaintiff: Raymond L. Hall and Sharon
Hall Defendant: AbbVie, Inc. and Abbott
Laboratories, Inc. Case Number: 1:2018cv00064 Filed: January 4, 2018 Court: Illinois Northern District Court Office: Chicago Office County: Cook Presiding Judge: Matthew F. Kennelly Nature of Suit: Other Cause of Action: 28:1332 Jury Demanded By: Plaintiff Busch et al v. AbbVie, Inc. et al Plaintiff: Kenneth Busch and Jolie Lyn
Busch Defendant: AbbVie, Inc. and Abbott
Laboratories, Inc. Case Number: 1:2018cv00043 Filed: January 3, 2018 Court: Illinois Northern District Court Office: Chicago Office County: Cook Presiding Judge: Matthew F. Kennelly Nature of Suit: Other Cause of Action: 28:1332 Jury Demanded By: Plaintiff Townsend v. AbbVie Inc. et al Plaintiff: Ronald E Townsend , Jr. Defendant: AbbVie Inc., Abbott
Laboratories, Inc., AbbVie Products LLC, Unimed Pharmaceuticals, LLC and
Besins Healthcare, S.A. Case Number: 1:2018cv00010 Filed: January 2, 2018 Court: Illinois Northern District Court Office: Chicago Office County: Cook Presiding Judge: Matthew F. Kennelly Nature of Suit: Other Cause of Action: 28:1332 Jury Demanded By: Plaintiff |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
TRADEMARKS |
CECON VITAMIN PREPARATION CONTAINING VITAMIN C Owned by: ABBVIE INC. Serial Number: 71488181 SURBEX MULTIPLE VITAMIN PREPARATION Owned by: ABBVIE INC. Serial Number: 71501298 TRIDIONE ANTICONVULSANT INTENDED FOR USE IN
TREATMENT OF THE PETIT MAL TRIAD AND OTHER CONVULSIVE DISORDERS Owned by: ABBVIE INC. Serial Number: 71531173 DULCET ORALLY ADMINISTRABLE TABLETS CONTAINING
VARIOUS MEDICINAL AGENTS AND DRUGS INTENDED FOR MEDICAL USES SUCH AS:
ANALGESICS… Owned by: ABBVIE INC. Serial Number: 71531573 SYNTHROID SYNTHETIC THYROXINE FOR TREATMENT OF
MYXEDEMA, CRETINISM, AND VARIOUS OTHER HYPOMETABOLIC STATES Owned by: ABBVIE INC. Serial Number: 71631584 FILMTAB TASTE-INHIBITING COATING ON ORALLY
ADMINISTERED MEDICINAL TABLETS Owned by: ABBVIE INC. Serial Number: 71665334 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SUMMARY
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
AbbVie Inc. discovers, develops,
manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy
administered as a subcutaneous injection to treat autoimmune diseases;
IMBRUVICA, an oral therapy for the treatment of patients with chronic
lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or
without ribavirin, for the treatment of adults with genotype 1 chronic
hepatitis C. It has 29.000 regular employees. It
operates nationally and internationally, mainly importing from India,
Singapore, Belgium and the Netherlands. The company shows positive profitability
in its last financial figures. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RISK
INFORMATION
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
DEBTS |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
PAYMENTS |
Regular |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
CASH FLOW |
Normal |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
STATUS |
Active |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INTERVIEW
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
NAME |
Amanda |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
POSITION |
Operator |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
COMMENTS |
She confirmed the name of the company, the
address of the headquarters and location, the date of creation of the
company, the number of employees and the name of the Chief Executive Officer. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
INR 63.67 |
|
|
1 |
INR 86.11 |
|
Euro |
1 |
INR 76.59 |
|
US Dollar |
1 |
INR 63.48 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
VAR |
|
|
|
|
Report Prepared
by : |
TRU |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably
on secured basis |
|
D |
High Risk |
Business dealing not recommended or on
secured terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the
business is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.